Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
- PMID: 37991771
- DOI: 10.1001/jamaoncol.2023.5004
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?
Comment on
-
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial.JAMA Oncol. 2024 Jan 1;10(1):43-51. doi: 10.1001/jamaoncol.2023.5013. JAMA Oncol. 2024. PMID: 37991747 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
